Paricalcitol.
Research-backed compound with potential health benefits. Synthetic vitamin D2 analog. Brand name Zemplar.
Reviewed March 2026
- Category
- Compound
What Paricalcitol is, and what it does.
- Does it work
- Medical treatment for a specific condition. Not a supplement option.
- How much to take
- There's no self-directed amount here. It's a prescription medicine, dosed and adjusted by a clinician against blood work, usually around 1 to 2mcg a day.
- Time to feel it
- Parathyroid hormone falls over the first weeks, and that is followed on blood tests rather than by sensation. Calcium and phosphate are checked alongside it.
- The first dose
- Day one passes quietly. Receptor binding starts straight away, and the change shows up on the next set of blood results rather than in how you feel.
- With regular use
- Across months, the prescriber follows parathyroid hormone, calcium and phosphate and adjusts the dose. It's monitored medicine rather than a background daily habit.
- How well tolerated
- Prescription only and monitored. Rising blood calcium is the main watch point, and medicines that induce or inhibit liver enzymes change how much of it you're exposed to.
- How it feels
- There's no felt effect. If calcium climbs too far, people can notice nausea, thirst or a metallic taste, which is why the blood work runs on a schedule.
- The overlooked benefit
- It isn't a vitamin D supplement. It activates the receptor directly and doesn't raise your 25-hydroxyvitamin D reading, so a vitamin D level test won't show that you take it.
1 to 2mcg a day is where Paricalcitol works.
Source: Teng et al., N Engl J Med, 2003; Sprague et al., Kidney Int, 2003
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Paricalcitol is documented in the library. The clinical read is in the queue. Nothing about the strength of the research prints until the read is done.
- parathyroid hormone suppressionMeta-analysis
- vitamin D receptor activation without a liver or kidney conversion stepNarrative review
- less effect on blood calcium than calcitriol at equal parathyroid hormone suppressionRandomised trial
- urinary albumin, a marker rather than an outcomeRandomised trial
Questions people ask about Paricalcitol.
- When should I take it?
- Timing matters less than consistency. Pick a time that works for you and take it daily.
- Can I take it with other supplements?
- Usually fine. The main thing to watch is not doubling up on the same ingredient from different products. If you're on prescription meds, check with your pharmacist first.
- Any side effects to watch for?
- Most people tolerate it well at recommended doses. GI upset is the most common complaint with any supplement. Start with a lower dose and work up. If something feels off, stop and reassess.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Paricalcitol activates the vitamin D receptor and raises expression of the intestinal calcium transport machinery. Adding a large calcium load pushes serum calcium in the same direction, so the two are additive and normally monitored together.
Calcium carbonate contributes both an absorbable calcium load and gut phosphate binding, while paricalcitol independently raises absorption of both minerals. The calcium arms of the two add together.
Vitamin D receptor activation increases intestinal phosphate transport alongside calcium. A supplemental phosphate load compounds the same shift in serum phosphate.
Cholecalciferol is converted to calcitriol, which binds the same vitamin D receptor paricalcitol occupies. Running both means two ligands acting at one receptor, so the calcium and phosphate effects add.
Cholecalciferol raises circulating 25-hydroxyvitamin D and downstream calcitriol, a full agonist at the receptor paricalcitol already activates. The signalling is additive rather than complementary.
Calcifediol is one hydroxylation away from calcitriol, the natural ligand of the receptor paricalcitol binds. Supplying it increases native agonist alongside the analogue.
Ergocalciferol is metabolised to 1,25-dihydroxyvitamin D2, which activates the same nuclear receptor. Its calcium and phosphate effects sit on top of the analogue's.
Vitamin D receptor activation raises expression of osteocalcin and matrix Gla protein, and both stay inactive until vitamin K carboxylates their glutamate residues. Menaquinone status determines whether those calcium handling proteins can function.
The hydroxylases that build and clear vitamin D metabolites are magnesium-dependent, and magnesium also participates in parathyroid hormone secretion. Magnesium status shapes the background the analogue acts against.
Vitamin D receptor signalling requires dimerisation with the retinoid X receptor, whose natural ligand is 9-cis retinoic acid, a vitamin A metabolite. The complex binds vitamin D response elements in target gene promoters. Retinoid status is therefore part of the machinery any vitamin D receptor activator, including paricalcitol, works through.
Vitamin D receptor signalling raises transcription of osteocalcin and matrix Gla protein, both of which need vitamin K-dependent gamma-carboxylation of glutamate residues before they can bind calcium. Without adequate vitamin K the induced protein is made but stays undercarboxylated. The relationship is sequential rather than additive.
Paricalcitol appears alongside glutathione and malondialdehyde measurements in rodent models, where those markers track oxidative state rather than any clinical result. There is no human study of the two given together. This is a co-studied laboratory pairing and nothing stronger.
Nothing specific on file for Paricalcitol. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.What Paricalcitol actually does.
Paricalcitol is a synthetic, lab-made version of active vitamin D that differs structurally from the natural hormone in a couple of specific spots.
It attaches directly to the vitamin D receptor without needing to be converted first, unlike some natural vitamin D forms that must be processed by the liver and kidney before they become active.
Once attached to its receptor, it pairs with another receptor and binds to specific spots on DNA, including one tied to a hormone gland, where it turns down that gene's activity.
It's cleared from the body mainly by liver and gut enzymes, so drugs that speed up or slow down those enzymes change how much of it stays in the body.
Where Paricalcitol comes from.
This is a laboratory-built version of the active form of vitamin D, with one part of its structure deliberately removed. Nothing in nature makes it, so every gram is synthesised and purified in a pharmaceutical plant. Because the dose is measured in millionths of a gram, the finished product is a solution in oil or solvent rather than a powder.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
Synthesis begins from ergocalciferol-derived fragments or from separately built CD-ring and A-ring pieces that carry the vitamin D2 side chain.
The defining 19-nor modification is introduced by building or modifying the A-ring so the exocyclic methylene at C19 is absent, then coupling it to the side-chain fragment, commonly by a convergent Wittig-Horner or Trost-type coupling.
The 1-alpha and 25-hydroxyl groups are installed or carried through protected, then deprotected, so the finished molecule needs no metabolic activation.
Secosteroid syntheses generate closely related isomers, so preparative chromatography followed by crystallisation is used to reach pharmaceutical purity.
Content and related substances are set by validated chromatographic assay against a reference standard, with isomeric impurities individually limited.
The purified solid is dissolved in either a medium-chain triglyceride vehicle for soft capsule filling or a propylene glycol and ethanol vehicle for injection, under light protection and inert headspace.
Getting Paricalcitol from food.
The whole-food sources on file. A supplement closes the gap, it does not replace dinner.
A gram-for-gram figure (how much of each you would eat to match a dose) will appear here once it is sourced and reviewed. This page will not print a number it cannot cite.
The forms it comes in.
The essence, in one line each.
- Pooling trials in adults with reduced kidney function, oral paricalcitol was associated with lower C-reactive protein, a blood marker of inflammation rather than a health outcome.Meta-analysis. Arabi et al., 2024 (BMC pharmacology & toxicology). PMID 38395972 β
- In adults during the first year after a kidney transplant, paricalcitol showed no detectable difference in the calcification propensity of serum compared with control, which is a failure to find a difference rather than evidence there is none.Randomised trial. Ussif et al., 2018 (BMC nephrology). PMID 30134956 β
- Parathyroid hormone lowering was compared between paricalcitol and calcitriol in people on maintenance haemodialysis. Parathyroid hormone is a laboratory marker and the comparison is observational rather than randomised.Cohort study. Murt A et al., 2025 (World Journal of Nephrology). PMID 41479833 β
These are the studies our verdict leans on, chosen from the 1,097 we read for Paricalcitol. The full linked list is below.
The studies, linked.
12 sources behind our Paricalcitol verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialThe PRIMO Study: Paricalcitol Capsules Benefits in Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4ClinicalTrials.gov βPhase 3, 227 participants, Completed
- Clinical trialEfficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Renal Transplantation.ClinicalTrials.gov βPhase 4, 148 participants, Completed
- Clinical trialEffectiveness and Safety of a 6-Month Treatment With IV Zemplar in Patients on Hemodialysis and With Secondary Hyperparathyroidism Using iPTH/100 as Initial DoseClinicalTrials.gov βPhase 4, 100 participants, Completed
- Clinical trialTrial to Optimize Mineral Outcomes in End Stage Renal Disease (ESRD) PatientsClinicalTrials.gov βPhase 4, 92 participants, Completed
- Clinical trialAn Open-Label, Repeated-Dose Safety, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Oral CTAP101 Capsules, Immediate- Release (IR) Calcifediol, High-Dose Cholecalciferol, and Paricalcitol Plus Low-Dose Cholecalciferol in Patients With Secondary Hyperparathyroidism, Stage 3 or 4 Chronic Kidney Disease and Vitamin D InsufficiencyClinicalTrials.gov βPhase 4, 69 participants, Completed
- Clinical trialSafety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)ClinicalTrials.gov βPhase 3, 68 participants, Completed
- Clinical trialEffect of Paricalcitol Over Vessel Wall: Pleiotropic Analogues Vitamin D EffectsClinicalTrials.gov βPhase 4, 50 participants, Terminated
- Clinical trialThe Effect of Paricalcitol Versus Placebo on Plasma N-Terminal-proBNP in Patients With Type 1 Diabetes Mellitus and Diabetic NephropathyClinicalTrials.gov βPhase 4, 48 participants, Completed
- Clinical trialEffects of 19-nor-1Ξ±-dihydroxyvitamin D2 (Paricalcitol) Versus Placebo on Oxidative Stress and Vascular Reactivity in CKD PatientsClinicalTrials.gov β41 participants, Completed
- Clinical trialA Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Paricalcitol as Pre-operative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the PancreasClinicalTrials.gov βPhase 2, 40 participants, Completed
- Clinical trialReno- and Vascular Protective Effect of a Low-calcemic Vitamin-D-analogue (Paricalcitol) in Stage III-IV Chronic Kidney DiseaseClinicalTrials.gov βPhase 2, 30 participants, Completed
- Clinical trialA Phase 2, Open-Label, Multicenter, Multi-Dose Study to Evaluate the Pharmacokinetics and Tolerability of Paricalcitol Injection in Chronic Kidney Disease Stage 5 Subjects With Secondary Hyperparathyroidism Undergoing HemodialysisClinicalTrials.gov βPhase 2, 25 participants, Completed
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
Problems people have reported.
Read this carefully. These are 19,513 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Paricalcitol is, not how risky it is. A report is not proof Paricalcitol caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.